Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.68
+0.21 (0.86%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 30.11, with a low estimate of 10 and a high estimate of 65. The average target predicts an increase of 22.00% from the current stock price of 24.68.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 3 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +29.66% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +163.37% | Apr 8, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -2.76% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +29.66% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $70 | Strong Buy | Maintains | $57 → $70 | +183.63% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
767.42M
from 700.97M
Increased by 9.48%
Revenue Next Year
854.19M
from 767.42M
Increased by 11.31%
EPS This Year
2.88
from -2.15
EPS Next Year
3.70
from 2.88
Increased by 28.23%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 813.7M | 966.5M | 1.1B | ||
| Avg | 767.4M | 854.2M | 940.3M | ||
| Low | 725.2M | 769.8M | 798.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1% | 25.9% | 27.0% | ||
| Avg | 9.5% | 11.3% | 10.1% | ||
| Low | 3.5% | 0.3% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.53 | 4.74 | 6.28 | ||
| Avg | 2.88 | 3.70 | 4.49 | ||
| Low | 2.32 | 2.73 | 3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 64.5% | 69.9% | ||
| Avg | - | 28.2% | 21.6% | ||
| Low | - | -5.1% | -16.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.